4/A
Changes in Ownership
Amylyx Pharmaceuticals, Inc. Filed Acc 0000899243-23-009602
Chief Financial Officer sold 32,500 shares at an average $31.89 ($1,036,459)
- Chief Financial Officer acquired 32,500 shares (option exercise)
- Chief Financial Officer acquired 21,667 shares (grant or award)
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| FRATES JAMES M Chief Financial Officer | 2023-03-16 | Option exercise | +32,500 | $6.88 | $223,600 | 66,509 | D |
| FRATES JAMES M Chief Financial Officer | 2023-03-16 | Sale | −30,796 | $31.86 | $981,139 | 35,713 | D |
| FRATES JAMES M Chief Financial Officer | 2023-03-16 | Sale | −1,704 | $32.46 | $55,320 | 34,009 | D |
| FRATES JAMES M Chief Financial Officer | 2023-03-16 | Grant or award | +21,667 | 55,676 | D | ||
| Derivatives | |||||||
| FRATES JAMES M Chief Financial Officer | 2023-03-16 | Grant or award · Stock Option (right to buy) | +97,500 | 97,500 | D | ||
| FRATES JAMES M Chief Financial Officer | 2023-03-16 | Option exercise · Stock Option (right to buy) | −32,500 | 414,500 | D | ||
| Open-market sales · 32,500 sh · avg $31.89 · $1,036,459 | |||||||
Loading xslF345X04/doc4a.xml…